Aprea Therapeutics Inc (APRE)
Aprea Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapies based on synthetic lethality and DNA damage response pathways. The company’s pipeline includes APR-1051, an orally available small-molecule WEE1 kinase inhibitor being evaluated in a Phase 1 study for patients with advanced solid tumors with biomarkers, and ATRN-119, an ATR inhibitor in Phase 1/2a testing for solid tumor indications. Aprea Therapeutics is headquartered in Doylestown, Pennsylvania. Its common stock is listed on the NASDAQ exchange under the symbol APRE.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-APRE
|
$0.94
|
28.7% Upside
|
Undervalued
|
$3.73
|
410.0% Upside
|
Bargain
|
Fair
|
0.0%
|
November 5, 2026
|
0.2x
|
1,788.7x
|
9.222 M
|
-31.231 M
|
0.0%
|
62.8%
|
-5.8
|
99.0%
|
